A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate E7107 in patients with solid tumors. This is an open label, dose-escalation study of E7107. The maximum tolerated dose (MTD) of the single agent will be established by determining the occurrence of dose limiting toxicities during the first three weeks of therapy (Cycle 1). Patients in this study will be treated at multiple dose levels, starting at 0.6 mg/m\^2. Patients will receive E7107 as a 30-minute intravenous infusion on Days 1 and 8 every 21 Days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours

NCT00459823

Cancer

SUSPENDED PHASE1

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

NCT00280397

Cancer: Solid Tumors

COMPLETED PHASE1

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

NCT00794781

Advanced Solid Tumors

COMPLETED PHASE1

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

NCT00165802

Cancer, Malignant Tumors

COMPLETED PHASE1

A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

NCT00869895

Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

E7107

Intervention Type DRUG

E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

E7107

E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with histologically and/or cytologically confirmed solid tumors who have progressed after receiving approved therapies for their disease and for whom no effective therapies are available.
2. Surgery and radiotherapy must have been completed at least four weeks prior to study entry, and prior chemotherapy and other anti-cancer therapy, excluding bisphosphonates at a steady dose level, must have been discontinued 2 to 3 weeks previously. All acute toxicities related to these treatments must have resolved.
3. Aged ≥ 18 years
4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
5. Written informed consent prior to any study specific screening procedures, which will include mandatory consent to provide a blood sample specifically for pharmacogenomic analysis, with the understanding that the patient may withdraw consent at any time without prejudice. Tumor biopsy for pharmacogenomic (PG) analysis will be voluntary.
6. Willing and able to comply with the protocol for the duration of the study.
7. Anticipated life expectancy \> three months.

Exclusion Criteria

Patients with the following characteristics will not be eligible for the study.

1. Symptomatic or progressive brain tumors or brain or leptomeningeal (CNS) metastases requiring clinical intervention, except if they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least two weeks before starting treatment with E7107.
2. Any of the following laboratory parameters:

1. hemoglobin \< 9 g/dL (5.6 mM)
2. neutrophils \< 1.5 x 10\^9/L
3. platelets \< 100 x 10\^9/L
4. serum bilirubin \> 25 μM (1.5 mg/dL)
5. liver function tests (defined as AST and ALT) with values \> 3 x ULN (5 x ULN if liver metastases are present)
6. serum creatinine \> 1.5 x ULN or creatinine clearance \< 40 mL/min.
3. Positive history of HIV, active hepatitis B or active hepatitis C or severe/uncontrolled intercurrent illness or infection.
4. Clinically significant cardiac impairment or unstable ischemic heart disease (greater than Class II according to New York Heart Association (NYHA) classification) including a myocardial infarction within six months of study start.
5. Bleeding or thrombotic disorders, or using therapeutic dosages of anticoagulants
6. History of alcoholism, drug addiction, or any psychiatric or psychological condition which, in the opinion of the Investigator, would impair study compliance.
7. Women who are pregnant or breast-feeding. Women of childbearing potential with either a positive serum pregnancy test at screening, a positive urine pregnancy test at the beginning of any cycle, or no pregnancy test. Women of childbearing potential unless using two forms of contraception, one of which must be a barrier method. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
8. Fertile men and fertile women who are not willing to use contraception, or fertile men or fertile women with a partner who is not willing to use contraception
9. Patients with a marked screening or baseline prolongation of QT/QTc interval using the Fridericia formula (ie, repeated demonstration of a QTc interval \> 450 msec); a history of additional risk factors for Torsade de Pointe (e.g., heart failure, hypokalaemia, history of Long QT Syndrome).
10. Patients who have had radiation to \>= 25% of their bone marrow (e.g., pelvic radiation).
11. Patients who have a history of previous Grade 2 or higher hypersensitivity to pladienolide B or derivatives and excipients of the formulation
12. Patients with significant comorbid disease or condition, which in the Investigator's opinion would exclude the patient from the study
13. Patients who have received an organ allograft ie, requiring immunosuppressive therapy
14. Beginning two weeks prior to dosing, patients are not allowed to take drugs that are strong CYP inhibitors (including grapefruit juice and herbal supplements) or inducers (including herbal supplements), or are metabolized by cytochrome P (CYPs) and known to have a narrow therapeutic window.
15. After MTD has been reached: Second malignancy within the past 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma of the skin.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No